MNST — Monster Beverage Corporation

Sentiment cooled hard after a hot run. MNST was up 12.55% over the six months into 2026-09-13 but down 5.61% over the prior month and 6.51% over three months, sitting ~13% under the 2026-07 high of $50.17. The trigger wasn't bad news - Q2 2026 (reported 2026-08-06) beat with +20.2% revenue and +19.6% net income - it was profit-taking into the 2-for-1 split (2026-08-11) and analyst chatter about growth normalizing, plus a fresh regulatory wrinkle in India. Street ratings remain constructive (roughly 23 Buys vs. 3 Sells; consensus 'Moderate Buy'), and the FMP price-target feed still shows a $98.22 consensus / $90-$105 range - which is pre-split and halves to ~$49 / $45-$52.50, matching the ~$50 median cited in the research brief. Net: the market is digesting, not abandoning.

Clear acceleration, not a blip. Revenue YoY went -2.3% (Q1 2025), +11.1% (Q2 2025), +16.8% (Q3 2025), +17.6% (Q4 2025), +26.9% (Q1 2026), +20.2% (Q2 2026) - from a soft comp base in early 2025 into a sustained high-teens/low-20s growth run. Margins inflected up with the revenue: operating margin bottomed at 21.0% in Q4 2024 (seasonally weakest), then printed 30.7%, 29.9%, 30.7%, 25.5%, 31.0%, 29.2% across the last six quarters, so the run-rate has moved from the mid-20s to a 29-31% band. Net margin is a steady ~23%. EPS compounded accordingly: FY2025 quarters of $0.225/$0.25/$0.265/$0.23 = $0.97 for the year, and H1 2026 delivered $0.29 + $0.30 = $0.59 versus $0.475 in H1 2025 (+24%). The one soft spot: Q2 2026 operating cash flow rose just 9.3% YoY ($509.2M vs. $466.0M) against 20.2% revenue growth - a working-capital timing gap that needs to close, not yet a trend.

Fair, with a justified premium - not cheap. As of 2026-09-13 the stock sat at 39.8x TTM EPS of $1.087 versus its own 5-year average trailing P/E of 38.6x, and 9.2x TTM sales versus a 5-year average of 8.4x. On forward numbers it looks better: ~37x the street's FY2026E EPS of $1.16 (which implies ~20% growth off FY2025's $0.97 actual) and ~32x my FY2027E of ~$1.36. The FMP-reported PEG of 1.15 uses a TTM growth rate and flatters the stock; on a forward 20% EPS growth rate the PEG is closer to 1.8-1.9. What you get for that multiple is genuinely elite: 55.5% gross margin, 29.2% operating margin, 23.1% net margin, 21.7% ROIC, zero long-term debt, 3.7x current ratio, and $2.19B of cash. The multiple is full but the quality and growth rate defend it; the P/B of 9.07 is inflated by buyback-shrunk equity and isn't a useful signal here. This is a 'you pay for it' valuation - the discount only appears if growth misses.

At $43.40 the market is already paying for continued ~20% EPS growth - it is not pricing a turnaround, and it is not pricing a stumble. FY2025 EPS was $0.97; FY2026 consensus is $1.16, which requires H2 2026 of roughly $0.57 against H2 2025's $0.495 (+15%). H1 2026 was +24%, so that bar looks achievable but not free. Two tells to watch: (1) whether operating cash flow growth catches back up to net income growth - Q2 2026's 9.3% OCF growth versus 20.2% revenue growth is the single most important earnings-quality question in the data; (2) whether international (+34.6% in Q2 2026, ~46% of revenue) keeps carrying the load as the US matures. If either cracks, a 39-40x TTM multiple has plenty of room to compress before fundamentals alone would justify it. Also flag: any '$98-$105' price target you see in third-party feeds is pre-split - halve it before comparing to the current quote.

As of 2026-09-13, the tape was corrective inside a still-intact uptrend. RSI(14) at 34.75 is weak-but-not-oversold; price was -5.36% versus the 20-day SMA, -7.60% versus the 50-day, but +3.52% versus the 200-day, with a 52-week range of $31.505-$50.17. Returns: -0.96% one week, -5.61% one month, -6.51% three months, +12.55% six months - short-term momentum has clearly rolled over while the longer-term trend has not broken. Implication for entry timing: there is no capitulation signal yet, so buying here is early rather than wrong. A more reliable trigger would be an RSI dip below 30 paired with a close back above the 20-day SMA (roughly the mid-$45s area) - or a successful retest of the 200-day, which is where the real trend line sits.

• International-versus-US divergence: international sales hit $1.16B in Q2 2026, +34.6% YoY and ~46% of total revenue, led by double-digit growth in Brazil, China and India, while the US market is maturing into low single digits - the growth rate of the whole company now depends on markets that carry higher regulatory and FX risk.
• India regulatory change (FSSAI, July 2026): India's food safety regulator ruled 'energy drink' is not a recognized legal category, forcing Monster, Red Bull and PepsiCo to relabel as 'caffeinated beverage' by 2026-09-29 - a live execution risk in one of the fastest-growing geographies.
• Inflation and consumer elasticity: Q2 2026 performance was driven in part by pricing actions; if the consumer weakens into late 2026, volume growth could give back what pricing added, and management has already flagged moderate pressure on volume.
• Competitive intensity in US energy drinks: Celsius and other challengers continue to press for shelf space, which is the most credible threat to Monster's domestic pricing power.
• Low-beta defensiveness: beta of 0.515 and a debt-free, cash-rich balance sheet make MNST a relative haven in a rotation to defensive consumer names, which supports the multiple even when growth moderates.

• Q3 2026 earnings, expected 2026-11-05, with early consensus around $0.30 EPS - the key test of whether the ~20% revenue growth run extends a fifth consecutive quarter.
• India relabeling deadline of 2026-09-29 - smooth compliance preserves the region's hyper-growth; shelving or distribution disruptions would be a visible growth hit.
• Continued international momentum in Brazil, China and India, which is currently doing all the heavy lifting on the growth rate.
• Remaining share repurchase authorization of roughly $900M, supported by $2.19B of cash and zero long-term debt.
• Coca-Cola system distribution expansion and new product/brand launches into adjacent categories (the split also lowers the per-share price and broadens retail accessibility).

• Growth normalization and multiple compression: at ~40x TTM earnings, even a deceleration from 20% to low-double-digit growth would likely compress the multiple faster than earnings grow.
• India and broader caffeine regulation: the September 2026 labeling deadline, plus any wider restriction on energy drinks (e.g. sales to minors), is a structural overhang on the fastest-growing region.
• Earnings quality gap: Q2 2026 operating cash flow grew only 9.3% versus 20.2% revenue growth, with a small positive accruals ratio (0.66% of assets) - if cash conversion doesn't normalize, the reported earnings are running slightly ahead of the cash.
• Competitive share loss in the US to Celsius and other challengers, which pressures both volume and pricing.
• Dependence on The Coca-Cola Company's bottling and distribution network - a structural advantage that is also a single point of operational leverage.
• Input cost, tariff and FX exposure as international revenue mix rises past 46%.

MNST is a genuinely high-quality, debt-free compounder - 55.5% gross margin, 29-31% operating margin, 21.7% ROIC, zero long-term debt, and revenue growth that reaccelerated from roughly flat in early 2025 to +20.2% in Q2 2026. The pullback from $50.17 to $43.40 has improved the entry point without damaging the story, but it is not a bargain: ~37x FY2026E and ~32x FY2027E already discount continued ~20% growth, which leaves the stock sensitive to any deceleration in international markets or the India relabeling disruption. My read is constructive but disciplined - a stock to accumulate on further weakness, not to chase, with the November 5 Q3 print and the September 29 India deadline as the near-term swing factors.

I applied a ~34.5x forward P/E to my FY2027E EPS of $1.36 (built from the street's FY2026E of $1.16, which itself is ~20% growth off FY2025's $0.97 actual, compounded one more year at ~17-18%), a multiple that sits just below Monster's 5-year average trailing P/E of 38.6x and equates to roughly a 1.9x PEG - defensible for a debt-free, 23%-net-margin, 21.7%-ROIC franchise, but not a discount. I cross-checked with a simplified DCF (TTM free cash flow of $2.10B grown 15% for five years, 4% terminal, 8% WACC), which produced ~$45.80 per share on ~1.96B post-split shares, and with the split-adjusted street consensus of ~$49. My $47.00 is the weighted midpoint of those methods and, versus the 2026-09-13 price of $43.40, implies roughly 8% upside - a fair-value estimate, not a re-rating call.